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Abstract
Background: The objective of this study is to evaluate rates of all-cause pneumonia among “at-risk” and “high-risk”
children and adults in Germany—in comparison with age-stratified healthy counterparts—during the period following
the 2006 recommendation for universal immunization of infants with pneumococcal conjugate vaccine.
Methods: Retrospective cohort design and healthcare claims information for 3.4 M persons in Germany (2009–2012)
were employed. Study population was stratified by age and risk profile (healthy, “at-risk” [with chronic medical
conditions], and “high-risk” [immunocompromised]). At-risk and high-risk conditions, as well as episodes of all-cause
pneumonia, were identified via diagnosis, procedure, and drug codes.
Results and discussion: Rates of all-cause pneumonia were 1.7 (95 % CI 1.7-1.8) to 2.5 (2.4-2.5) times higher among
children and adults with at-risk conditions versus healthy counterparts, and 1.8 (1.8-1.9) to 4.1 (4.0-4.2) times higher
among children and adults with high-risk conditions. Rates of all-cause pneumonia among at-risk persons increased
in a graded and monotonic fashion with increasing numbers of conditions (i.e., risk stacking).
Conclusions: An increased risk for all-cause pneumonia in German children and adults with a spectrum of medical
conditions persists in the era of widespread pneumococcal vaccination, and pneumonia risk in persons with ≥2 at-risk
conditions is comparable or higher than those with high-risk conditions.
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Background
Community-acquired pneumonia (CAP) is a frequent
cause of hospitalization and death in Germany. The inci-
dence of CAP has been estimated to be 3.7-10.1/1000
inhabitants [1], and over 259,000 German adults were
estimated to have been hospitalized for CAP in 2013 [2].
Ewig and colleagues observed that the incidence of CAP
increased with advancing age, and that overall in-
hospital mortality of CAP patients was 14 %, with the
highest mortality in persons with comorbid conditions;
among persons with malignancies, dementia, and pul-
monary diseases (other than chronic obstructive pulmon-
ary disease [COPD]), mortality was more than two-fold
higher than among those with no known underlying con-
ditions. Importantly, mortality risk was highest in the first
days after admission, suggesting that prevention strategies
may be more important than therapeutic approaches to
reduce mortality [3].
Streptococcus pneumoniae (pneumococcus) has been
reported to be one of the most common causes of am-
bulatory, hospitalized, and severe pneumonia among
adults throughout Europe [4, 5]. While it is widely rec-
ognized that persons with immunocompromising condi-
tions, as well as those with certain chronic illnesses,
were at increased risk of pneumococcal disease prior to
the widespread introduction of seven-valent pneumococ-
cal conjugate vaccine (PCV7) in the US and western
Europe, recent assessments of disease risk in populations
following mass vaccination of children with PCVs are
limited. The indirect effect of childhood immunization
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has led to impressive declines in the incidence of inva-
sive pneumococcal disease in US adults [6–11], but
more variable herd effects in western Europe [12]. Fur-
ther confirmation from additional populations as to the
magnitude of the increased risk of pneumococcal disease
associated with certain chronic medical conditions fol-
lowing introduction of pneumococcal conjugate vaccines
would be valuable for developing future vaccine policies
for the prevention of pneumonia.
We therefore employed a large German research data-
base to estimate rates of all-cause pneumonia—as a proxy
for pneumococcal disease—among persons with and with-
out one or more of the chronic illnesses included by the
German Committee on Vaccination (Ständige Impfkom-
mission [STIKO]) and/or the US Advisory Committee for
Immunization Practices (ACIP) as indications for pneumo-
coccal vaccination. We also examined disease rates among
persons with other conditions that might increase infection
risk based on limited data from other studies, including
three autoimmune diseases—rheumatoid arthritis, systemic
lupus erythematosus, and Crohn’s disease—as well as
neuromuscular (chiefly cerebral palsy)/seizure disorders
[13–16]. Finally, we examined the impact of risk stacking
among the at-risk population by estimating disease rates
within subgroups defined on the basis of the number of
concurrent conditions.
Methods
Data design and source
A retrospective cohort design and data from the Health
Risk Institute (HRI) Research Database spanning 2008–
2012 were employed. The HRI Database comprises
medical and drug claims from an age and gender repre-
sentative sample of 3.4 million persons covered by the
statutory health care system in Germany, approximately
4 % of the total population. The HRI Scientific Board
approved our study and granted access to the HRI
Research Database.
Data available from each medical claim include date/
quarter of service, place of service, diagnoses (Inter-
national Statistical Classification of Diseases and Related
Health Problems, 10th revision, German Modification
[ICD-10-GM]), procedures performed/services rendered,
and quantity of services. Data available for each drug
claim include the agent dispensed (as set forth by the Ana-
tomical Therapeutic Chemical [ATC] System), dispensing/
prescription date, and quantity dispensed. Medical and
drug claims also include amounts paid (i.e., reimbursed)
to providers by health insurers. Selected demographic and
eligibility information (including age/year of birth, sex,
dates of enrollment) also is available for persons in the
HRI Database. All data can be arrayed to provide a
detailed chronology of medical and pharmacy series used
by each insured member over time.
Insurance benefits extend to all healthcare services.
The HRI Database does not include data on clinical
parameters (e.g., lab results), quality of life, or markers
of disease severity because health insurers in Germany
are prohibited by federal law from having such informa-
tion. All patient-level data in the HRI Research Data-
base are de-identified to comply with German data
protection regulations. Use of the study database for
health services research is therefore fully compliant
with German federal law and, accordingly, IRB/ethical
approval was not needed.
Study population
The study population comprised persons who were
enrolled in a health insurer represented in the HRI Data-
base on January 1, 2009. Persons who were not continu-
ously eligible for health insurance benefits for at least one
year prior to January 1, 2009 were excluded from the
study population; less than 0.5 % of the population from
the HRI Database was excluded due to this criterion.
Infants <12 months of age as of this date were not subject
to this exclusionary criterion.
Study subjects were stratified based on their age
(<5, 5–17, 18–49, 50–59, and ≥60 years) and risk pro-
file (“at-risk”, “high-risk”, and “healthy”). Risk profiles
were defined based on the presence of medical condi-
tions that are indications for pneumococcal vaccin-
ation among children and adults including alcoholism,
asthma, chronic heart disease, chronic liver disease,
chronic lung disease, chronic renal failure, cochlear
implant, Crohn’s disease, diabetes, Down’s syndrome,
functional/anatomic asplenia, HIV, immunosuppres-
sant therapy, short gestation/low birthweight, smok-
ing, as well as those medical conditions hypothesized
to be associated with increased risk including neuro-
muscular/seizure disorders, rheumatoid arthritis, and
systemic lupus erythematosis [13–16]. The list of med-
ical conditions was based on recommendations for vaccin-
ation set forth by STIKO and/or ACIP, as well as other
conditions previously reported to confer an increased risk
of pneumococcal disease.
Immunocompetent persons with ≥1 chronic medical
condition were classified as at-risk; immunocomprom-
ised/immunosuppressed persons and those with a coch-
lear implant were classified as high-risk. At-risk and
high-risk were mutually exclusive categories and thus,
for example, persons considered immunosuppressed
due to cancer treatment were included in the high-risk
category only, even if they also had an at-risk condition.
Persons without evidence of at-risk or high-risk condi-
tions were classified as healthy. At-risk and high-risk
medical conditions were ascertained using ICD-10-
GM diagnosis codes recorded any time prior to the
beginning of the 2009 calendar year. Operational
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algorithms employed to identify at-risk and high-risk
conditions are available in Additional file 1: Table S1
and Additional file 2: Table S2, respectively, of the
online supplement.
Study measures
Episodes of all-cause pneumonia (i.e., all clinical cases
caused by all known and unknown pathogens, including S.
pneumoniae) were identified during the four-year period
beginning on January 1, 2009 and ending on December
31, 2012 or the date of health insurer disenrollment,
whichever occurred first. Episodes were identified using
operational algorithms based on corresponding diagnosis
codes (ICD-10-GM) in the principal or secondary pos-
ition, procedure codes for inpatient care (Operationen-
und Prozedurenschlüssel [OPS]), and ATC drug codes, as
set forth in the online supplement (Additional file 3: Table
S3); cases that were invasive (i.e., bacteremic) in nature
were excluded from consideration. Multiple episodes of
all-cause pneumonia for a given patient were included as
independent events if they were separated by ≥90 days.
Statistical analyses
Incidence rates of all-cause pneumonia episodes were
estimated for children and adults within each age group
by risk profile as well as individual medical condition,
and were expressed per 100,000 person-years. Rate ratios
for disease episodes among persons with at-risk and
high-risk conditions, respectively—overall and by indi-
vidual medical condition—versus their age-stratified
healthy counterparts were estimated using Poisson re-
gression (SAS v 9.3). Rates of disease and corresponding
rate ratios (vs. healthy counterparts) also were calculated




Children aged <5 years and 5–17 years contributed a
total of 0.5 million and 1.7 million person-years of ob-
servation, respectively. In these two age groups, 71 %
and 79 %, respectively, had none of the selected chronic
or immunocompromising conditions, 26 % and 19 %
had ≥1 at-risk condition (and no high-risk conditions),
and 3 % and 2 % had a high-risk condition.
Among those with at-risk conditions, chronic lung dis-
ease (68 % and 54 %) and asthma (23 % and 43 %) were
common; 17 % of children <5 years of age and 13 % of
children 5–17 years of age with at-risk conditions had
more than one condition.
Disease rates
Rates of all-cause pneumonia among children <5 years
and 5–17 years of age with at-risk conditions were 1.7
(95 % confidence interval [CI] 1.7-1.8) and 2.4 (2.3-2.5)
times the rates in their healthy counterparts, and rates
of all-cause pneumonia among high-risk children in
these age groups were 1.8 (1.8-1.9) and 2.9 (2.8-3.0)
times the rates in children without at-risk or high-risk
conditions (Table 1). Rate ratios for all-cause pneumonia
among children with at-risk conditions increased with
the number of such conditions compared with healthy
counterparts (Fig. 1). Among younger children, rate
ratios increased from 1.5 (1.5-1.5) for those with one
condition to 4.7 (4.6-4.7) for those with ≥3 conditions;
among older children, rate ratios increased from 2.0
(1.9-2.1) to 11.3 (11.0-11.5).
Adults
Characteristics
Persons aged 18–49 years, 50–59 years, and ≥60 years
contributed a total of 5.7 million, 2.0 million, and 3.5
million person-years of observation, respectively. Ap-
proximately 76 %, 60 %, and 36 %, respectively, had
none of the selected chronic or immunocompromis-
ing conditions. The prevalence of at-risk and high-risk
conditions increased with increasing age: 21 %, 33 %, and
45 % had at-risk conditions, and 3 %, 7 %, and 19 % had
high-risk conditions.
Among adults aged 18–49 years with at-risk condi-
tions, the most common conditions were chronic lung
disease (48 %), asthma (27 %), and chronic liver disease
(13 %). In adults 50–59 years of age, the most common
conditions were chronic lung disease (37 %), diabetes
(26 %), chronic liver disease (24 %), and chronic heart
disease (23 %). In adults ≥60 years of age, the most com-
mon conditions were chronic heart disease (46 %),
diabetes (41 %), chronic lung disease (30 %), and chronic
liver disease (20 %).
Disease rates
Adults aged 18–49, 50–59, and ≥60 years with at-risk
conditions had 2.2 (2.1-2.4), 2.3 (2.2-2.4), and 2.5 (2.4-
2.5) times the rates of all-cause pneumonia as their
healthy counterparts (Table 2). Corresponding rate ratios
for those with high-risk conditions were 3.2 (3.0-3.4), 3.7
(3.6-3.9), and 4.1 (4.0-4.2).
Rate ratios for all-cause pneumonia among adults with
at-risk conditions increased with the number of such con-
ditions compared with healthy counterparts (Fig. 2). Rates
among adults with two at-risk conditions were generally
similar to rates among adults with high-risk conditions,
and rates in adults with three or more at-risk conditions
were higher than those among adults with high-risk con-
ditions. Rates and rate ratios of all-cause pneumonia
among healthy, at-risk, and high-risk adults stratified by
additional age groups are available in Additional file 4:
Table S4 of the online supplement.
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Discussion
We undertook a large retrospective evaluation of rates
of all-cause pneumonia among “at-risk” and “high-
risk” children and adults in Germany—in comparison
with age-stratified healthy counterparts—in the period
following the 2006 recommendation for universal
immunization of infants with pneumococcal conjugate
vaccine. The results of this evaluation suggest that im-
munocompetent persons with comorbid conditions and
immunocompromised persons of all ages continue to suf-
fer a disproportionate burden of pneumonia in the era of
widespread pneumococcal vaccination [3, 17–21]. Both the
proportion of the German population with an at-risk or
high-risk condition and the incidence of CAP are reported
to climb with increasing age. Moreover, the results of this
study suggest that the risk of all-cause pneumonia among
children and adults with ≥2 at-risk conditions is compar-
able to, or exceeds, corresponding values among age-
stratified persons with high-risk conditions. Our data also
provide additional evidence in support of an increased risk
of all-cause pneumonia in adults with rheumatoid arthritis,
systemic lupus erythematosus, Crohn’s disease, and neuro-
muscular/seizure disorders [13, 22]. Such conditions are
not currently included within the STIKO or ACIP recom-
mendations for prevention.
Notwithstanding differences in study design and
methods between our evaluation and work by Ewig and
colleagues—including their use of records from all
hospitals in Germany (vs. claims information from an
age/gender-representative sample in our study), their
Table 1 Rates of all-cause pneumonia among healthy, at-risk, and high-risk children
All-Cause Pneumonia
No. of Person-Years Age <5 Years Age 5–17 Years
Age Age Rate Rate Ratiosa Rate Rate Ratiosa
<5 Years 5-17 Years per 100 K (95 % CI) per 100 K (95 % CI)
Risk Group
Healthy 360,184 1,318,738 3,779 1.0 730 1.0
At-Risk 129,895 310,546 6,555 1.7 (1.7, 1.8) 1,734 2.4 (2.3, 2.5)
Chronic heart disease 15,181 19,899 7,813 2.1 (2.0, 2.1) 2,055 2.8 (2.7, 2.9)
Chronic lung disease 88,323 169,241 6,539 1.7 (1.7, 1.8) 1,836 2.5 (2.4, 2.6)
Diabetes 680 5,595 5,886 1.6 (1.5, 1.6) 1,734 2.4 (2.3, 2.5)
Asthma 29,737 134,188 8,986 2.4 (2.3, 2.4) 1,994 2.7 (2.6, 2.9)
Alcoholism 0 2,092 0 0.0 (——) 813 1.1 (1.0, 1.2)
Chronic liver disease 241 2,074 14,099 3.7 (3.7, 3.8) 2,941 4.0 (3.9, 4.2)
Smokers 0 530 0 0.0 (——) 1,321 1.8 (1.7, 1.9)
Down's syndrome 473 1,318 14,579 3.9 (3.8, 3.9) 4,022 5.5 (5.3, 5.7)
Neuromuscular/seizure disorder 9,075 18,219 7,570 2.0 (2.0, 2.0) 2,898 4.0 (3.8, 4.1)
Short gestation/low birthweight 10,311 32 8,719 2.3 (2.3, 2.4) 6,250 8.6 (8.4, 8.8)
Rheumatoid 67 1,250 10,448 2.8 (2.7, 2.8) 960 1.3 (1.2, 1.4)
Rheumatoid arthritis 8 358 0 0.0 (——) 280 0.4 (0.3, 0.4)
Lupus 0 59 0 0.0 (——) 0 0.0 (——)
Crohn's 59 841 11,865 3.1 (3.1, 3.2) 1,307 1.8 (1.7, 1.9)
High-Risk 17,704 45,383 6,914 1.8 (1.8, 1.9) 2,131 2.9 (2.8, 3.0)
Cochlear implant 1,134 2,684 5,907 1.6 (1.5, 1.6) 2,906 4.0 (3.8, 4.1)
Functional/anatomic asplenia 850 2,347 9,175 2.4 (2.4, 2.5) 2,983 4.1 (3.9, 4.2)
HIV 318 1,287 3,769 1.0 (1.0, 1.0) 1,710 2.3 (2.2, 2.5)
Chronic renal failure 1,127 4,579 12,778 3.4 (3.3, 3.4) 3,036 4.2 (4.0, 4.3)
Immunosuppressants 905 4,893 9,720 2.6 (2.5, 2.6) 1,696 2.3 (2.2, 2.4)
Malignant neoplasms 854 4,669 7,263 1.9 (1.9, 2.0) 1,328 1.8 (1.7, 1.9)
Solid organ transplantation 76 326 34,354 9.1 (9.0, 9.2) 6,441 8.8 (8.6, 9.0)
Congenital immunodeficiency 13,227 29,420 6,328 1.7 (1.6, 1.7) 2,094 2.9 (2.7, 3.0)
Diseases of white blood cells 683 1,468 11,267 3.0 (2.9, 3.0) 2,247 3.1 (3.0, 3.2)
aRelative to healthy counterparts
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focus on an adult population (vs. children and adults),
and their focus on inpatient CAP (vs. inpatient and out-
patient all-cause pneumonia)—the results of our study
are largely consistent with their findings. Ewig et al.
identified cardiac, central nervous system, and pulmon-
ary disease (other than COPD), as well as diabetes and
COPD, as the five most prevalent comorbid conditions
in adults with hospitalized CAP. Similarly, we found
chronic lung disease, chronic heart disease, and diabetes
to be the most prevalent chronic diseases among
Germans with all-cause pneumonia; asthma and chronic
liver disease also were found to be common among
pneumonia cases.
Recent studies from the UK and US found that the el-
evated risk of pneumonia in adults with selected med-
ical conditions persisted during the era following the
introduction of pneumococcal conjugate vaccine, al-
though the magnitude of relative risk was not always
consistent [13, 22–24]. In our study, German children
under the age of 5 years with at-risk conditions accounted
for 26 % of this age cohort yet 36 % of all-cause pneumonia
cases; children aged 5–17 years with at-risk conditions
accounted for 19 % of this cohort but 34 % of all-cause
pneumonia cases. Comparable results for adults aged
<60 years were: 18–49 year-olds, 21 % of the cohort and
35 % of disease burden; 50–59 year-olds, 33 % of the co-
hort and 47 % of disease burden. Consistent with published
data from Shea and colleagues, we found increasing inci-
dence of pneumonia with increasing age in at-risk, high-
risk, and healthy persons, and relatively stable rate ratios,
suggesting that the relative increase in disease risk with age
is similar in all three groups [13].
We chose all-cause pneumonia as a proxy for pneumo-
coccal pneumonia based on several considerations. First,
studies in children demonstrate that identification of
pneumococcus as a cause of hospitalized pneumonia
substantially underestimates the role of pneumococcus
compared to the reduction in all-cause hospitalized pneu-
monia achieved following introduction of pneumococcal
conjugate vaccine [25, 26]. We believe the same challenge
would be relevant for the diagnosis of pneumococcal
pneumonia in adults in clinical settings. Moreover, oper-
ational algorithms for pathogen-specific cases of pneumo-
nia based on diagnosis codes typically lack adequate
sensitivity since diagnostic tests (i.e., culture, serological,
and polymerase chain reaction [PCR] tests, as well as inva-
sive sampling methods) are infrequently performed in
clinical practice. Thus, in the absence of concurrent
bacteremia, the diagnosis (and therefore coding) of
pneumococcal pneumonia underestimates disease burden.
Second, in the control group in the CAPiTA study, 22 %
(174 of 787) of episodes of CAP in adults ≥65 years of age
were due to vaccine serotypes representing a minimum
estimate of pneumococcal burden in this age group as
nonvaccine serotypes were not sought. Lastly, in the retro-
spective study by Shea and colleagues based on US health-
care claims data, the increased disease risk in “at-risk” and
“high-risk” subjects was comparable for both all-cause
pneumonia and pneumococcal pneumonia [13].
We note several other limitations that are inherent in
the use of healthcare claims data for retrospective stud-
ies such as this one. First, rates of all-cause pneumonia
may be misestimated somewhat due to the less than per-
fect sensitivity and specificity of our case-ascertainment
algorithm. However, to the extent this limitation impacts
rates in a proportional manner across age and risk
groups, rate ratios should be largely unaffected. Second,
use of operational algorithms and the left-truncation of
Fig. 1 Rates of all-cause pneumonia among children by number of risk conditions
Pelton et al. BMC Infectious Diseases  (2015) 15:470 Page 5 of 8
the study database undoubtedly resulted in the mis-
classification of risk profiles for some persons, including
both errors of omission and commission. For example,
diagnosis codes capturing smoking and alcoholism are
under-recorded in the study database, and procedures
(e.g., cochlear implant) performed prior to the beginning
of the study database were not observable. Unfortu-
nately, it was not possible to undertake a formal evalua-
tion—for example, via chart review or use of additional
data sources (e.g., electronic medical records)—of the
accuracy of these algorithms within the context of this
study. Third, data limitations precluded us from identify-
ing the specific pathogen/serotype causing disease; it
would be of interest to know the proportion of cases
due to individual pathogens/serotypes, and whether or
not they are included in PCV7, PCV10, PCV13, and
PPSV23 (or currently unavailable vaccines). Fourth, to
the extent pneumococcal vaccination status varies by
risk profile (i.e., likely to be higher uptake among high-
risk and at-risk persons vs. healthy persons), rate ratios
may be downwardly biased. Fifth, while the HRI Data-
base comprises claims data from individuals covered by
the German statutory health care system and is repre-
sentative of the German population in terms of age and
gender, it is unknown whether the HRI Database is rep-
resentative of the German population in terms of race,
Table 2 Rates of all-cause pneumonia among healthy, at-risk, and high-risk adults
All-Cause Pneumonia
No. of Person-Years Age 18–49 Years Age 50–59 Years Age ≥60 Years









(95 % CI) per
100 K




Healthy 4,334,344 1,194,431 1,308,873 441 684 1,439
At-Risk 1,197,718 648,276 1,575,635 975 2.2 (2.1, 2.4) 1,554 2.3 (2.2, 2.4) 3,547 2.5 (2.4, 2.5)
Chronic heart disease 116,350 145,449 703,271 1,147 2.6 (2.5, 2.8) 1,780 2.6 (2.5, 2.7) 4,451 3.1 (3.0, 3.2)
Chronic lung disease 579,980 238,260 466,695 1,088 2.5 (2.3, 2.6) 2,195 3.2 (3.1, 3.3) 5,246 3.6 (3.5, 3.7)
Diabetes 97,028 165,443 643,437 1,115 2.5 (2.4, 2.7) 1,592 2.3 (2.2, 2.4) 3,736 2.6 (2.5, 2.7)
Asthma 323,267 102,513 165,056 1,112 2.5 (2.4, 2.7) 2,314 3.4 (3.2, 3.5) 4,621 3.2 (3.1, 3.3)
Alcoholism 33,593 25,488 27,142 1,578 3.6 (3.4, 3.8) 2,754 4.0 (3.9, 4.2) 5,626 3.9 (3.8, 4.0)
Chronic liver disease 154,804 154,616 321,444 1,015 2.3 (2.2, 2.5) 1,419 2.1 (2.0, 2.2) 2,861 2.0 (1.9, 2.1)
Smokers 38,316 22,141 19,819 1,133 2.6 (2.4, 2.7) 2,529 3.7 (3.6, 3.8) 5,535 3.8 (3.7, 3.9)
Down's syndrome 2,926 451 139 2,016 4.6 (4.4, 4.8) 7,987 11.7 (11.4, 11.9) 11,471 8.0 (7.8, 8.1)
Neuromuscular/seizure disorder 49,368 18,445 36,733 1,669 3.8 (3.6, 4.0) 2,483 3.6 (3.5, 3.8) 6,711 4.7 (4.6, 4.8)
Short gestation/low birthweight 1,607 0 4 622 1.4 (1.3, 1.5) 0 0.0 (——) 0 00.0 (——)
Rheumatoid 48,367 35,563 83,318 1,164 2.6 (2.5, 2.8) 1,696 2.5 (2.4, 2.6) 3,842 2.7 (2.6, 2.8)
Rheumatoid arthritis 26,323 28,126 76,319 1,193 2.7 (2.6, 2.9) 1,582 2.3 (2.2, 2.4) 3,830 2.7 (2.6, 2.7)
Lupus 1,624 794 1,028 2,402 5.5 (5.2, 5.7) 3,777 5.5 (5.3, 5.7) 5,640 3.9 (3.8, 4.0)
Crohn's 21,202 7,128 6,633 990 2.2 (2.1, 2.4) 1,796 2.6 (2.5, 2.7) 3,317 2.3 (2.2, 2.4)
High-Risk 181,558 132,436 630,789 1,411 3.2 (3.0, 3.4) 2,559 3.7 (3.6, 3.9) 5,852 4.1 (4.0, 4.2)
Cochlear implant 719 542 2,787 1,669 3.8 (3.6, 4.0) 2,768 4.0 (3.9, 4.2) 4,629 3.2 (3.1, 3.3)
Functional/anatomic asplenia 11,350 3,580 8,583 1,665 3.8 (3.6, 4.0) 4,134 6.0 (5.9, 6.2) 9,705 6.7 (6.6, 6.9)
HIV 7,940 2,692 7,386 1,952 4.4 (4.2, 4.6) 2,192 3.2 (3.1, 3.3) 3,994 2.8 (2.7, 2.9)
Chronic renal failure 38,170 36,522 266,953 1,776 4.0 (3.8, 4.2) 3,313 4.8 (4.7, 5.0) 8,114 5.6 (5.5, 5.8)
Immunosuppressants 84,727 81,587 381,069 1,779 4.0 (3.9, 4.2) 2,787 4.1 (3.9, 4.2) 5,053 3.5 (3.4, 3.6)
Malignant neoplasms 82,755 80,199 379,086 1,556 3.5 (3.4, 3.7) 2,557 3.7 (3.6, 3.9) 4,957 3.4 (3.4, 3.5)
Solid organ transplantation 2,574 1,850 2,924 8,509 19.3 (18.9, 19.7) 12,056 17.6 (17.3, 17.9) 15,768 11.0 (10.8, 11.1)
Congenital immunodeficiency 38,927 10,800 16,179 1,123 2.5 (2.4, 2.7) 2,935 4.3 (4.1, 4.4) 6,385 4.4 (4.3, 4.5)
Diseases of white blood cells 9,468 5,779 13,734 1,986 4.5 (4.3, 4.7) 3,063 4.5 (4.3, 4.6) 6,407 4.5 (4.3, 4.6)
aRelative to healthy counterparts
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socio-economic factors, and other such characteristics.
Finally, while the HRI Research Database should be suf-
ficiently large to compare (robustly) rates of disease be-
tween age-specific at-risk and high-risk persons versus
their healthy counterparts, comparisons of rates within
subgroups defined on the basis of individual conditions
are undoubtedly underpowered in many instances and
should be interpreted with caution.
Conclusion
Our data confirm previous reports of enhanced risk in in-
dividuals with multiple comorbid conditions [13, 22, 27].
Expanded use of pneumococcal conjugate vaccines have
been proposed to prevent pneumococcal pneumonia in
high-risk individuals and those 65 years of age and older.
In conjunction with recent publications [11, 13, 22, 23, 28],
our findings suggest that the highest rates of all-cause
pneumonia, and presumably pneumococcal pneumonia,
occur in individuals with multiple comorbid conditions in
the absence of immune deficiency. In adults with trad-
itional high-risk conditions, high mortality rates have been
reported [3]. If high mortality rates from all-cause pneu-
monia and pneumococcal pneumonia also are observed in
individuals with multiple at-risk conditions in the absence
of immune compromise, further effort to understand the
underlying susceptibility could lead to additional strategies
for prevention.
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